MetaStat Saham

MetaStat Beban Bunga

Beban Bunga dari MetaStat (MTST) pada 12 Agu 2026 adalah 368.900,00 USD. Tahun sebelumnya, Beban Bunga adalah 1,96 Juta. USD — perubahan sebesar -81,16% (lebih rendah).

Beban Bunga

368.900,00USD

YoY

-81,16%

Terakhir Diperbarui:

Beban Bunga dari MetaStat adalah 2026 368.900,00 USD. Beban Bunga dari MetaStat adalah 2025 1,96 Juta. USD. Menurun -81,16% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

MetaStat Analisis saham

Apa yang dilakukan MetaStat? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham MetaStat

Beban Bunga MetaStat adalah 368.900,00 USD pada tahun 2026.

Beban Bunga dari MetaStat berubah dari 1,96 Juta. USD menjadi 368.900,00 USD, mewakili perubahan -81,16%. Nilainya lebih rendah daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap Beban Bunga MetaStat sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

Beban bunga mewakili biaya peminjaman. Beban bunga yang lebih tinggi dapat menunjukkan perusahaan yang sangat terleverage.

USD Beban Bunga adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak MetaStat Beban Bunga secara historis dan real-time.

Access this data via the Eulerpool API

Laporan Laba Rugi — MetaStat

Semua Metrik Kunci — MetaStat